Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.
The claim that funded class actions are the main factor impacting the D&O premium increases and stultifying business in Australia is a specious argument. The reality is that the primary reason for the increase in the cost of D&O liability insurance is the extent of corporate wrongdoing, says Omni Bridgeway’s Andrew Saker.
Three law firms will represent the insurers in new proceedings launched to resolve a $46 million insurance question delaying settlement of two shareholder class actions against sandlewood producer Quintis, bringing the total number of law firms working on the class action to eight.
Motorola has slammed Chinese radio manufacturer Hytera’s “disruptive and unsatisfactory” request to adjourn a highly anticipated copyright trial over the alleged theft of source code which is due to begin in three weeks.
Billionaire real estate developer Harry Triguboff and his company Meriton have hit back at claims by the former group general counsel of the property giant […]
A former high-flying trader is taking ANZ to court alleging the bank dismissed him for making complaints about attempted manipulation of a key interest rate and not, as the bank claims, for his “offensive” chats with other traders.
A judge has adjourned an interlocutory application because of deficient pleadings in a class action brought against three medical device manufacturers and a former doctor […]
A delegate of IP Australia has tossed opposition by veterinary pharmaceutical company Norbrook Laboratories to a patent by rival animal health specialist Bayer New Zealand […]
A court has appointed provisional liquidators to the IPO Wealth Group, rejecting claims by the firm’s sole director that the move would severely damage his reputation and that of the wider Mayfair group.